307 related articles for article (PubMed ID: 22169642)
21. Aberrant promoter methylation of FBLN-3 gene and clinicopathological significance in non-small cell lung carcinoma.
Wang R; Zhang YW; Chen LB
Lung Cancer; 2010 Aug; 69(2):239-44. PubMed ID: 19913326
[TBL] [Abstract][Full Text] [Related]
22. ASPP1 and ASPP2: common activators of p53 family members.
Bergamaschi D; Samuels Y; Jin B; Duraisingham S; Crook T; Lu X
Mol Cell Biol; 2004 Feb; 24(3):1341-50. PubMed ID: 14729977
[TBL] [Abstract][Full Text] [Related]
23. Down-regulation of PAX6 by promoter methylation is associated with poor prognosis in non small cell lung cancer.
Zhang X; Yang X; Wang J; Liang T; Gu Y; Yang D
Int J Clin Exp Pathol; 2015; 8(9):11452-7. PubMed ID: 26617874
[TBL] [Abstract][Full Text] [Related]
24. The correlation between aberrant connexin 43 mRNA expression induced by promoter methylation and nodal micrometastasis in non-small cell lung cancer.
Chen JT; Cheng YW; Chou MC; Sen-Lin T; Lai WW; Ho WL; Lee H
Clin Cancer Res; 2003 Sep; 9(11):4200-4. PubMed ID: 14519646
[TBL] [Abstract][Full Text] [Related]
25. Reduced expression of liver kinase B1 and Beclin1 is associated with the poor survival of patients with non-small cell lung cancer.
Jiang L; Liang X; Liu M; Wang W; Ma J; Guo Q; Han L; Yang C; Nan K
Oncol Rep; 2014 Nov; 32(5):1931-8. PubMed ID: 25175672
[TBL] [Abstract][Full Text] [Related]
26. Significance of methylation status and the expression of RECK mRNA in lung tissue of patients with NSCLC.
Pesta M; Kulda V; Topolcan O; Safranek J; Vrzalova J; Cerny R; Holubec L
Anticancer Res; 2009 Nov; 29(11):4535-9. PubMed ID: 20032402
[TBL] [Abstract][Full Text] [Related]
27. 5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer.
Zöchbauer-Müller S; Fong KM; Maitra A; Lam S; Geradts J; Ashfaq R; Virmani AK; Milchgrub S; Gazdar AF; Minna JD
Cancer Res; 2001 May; 61(9):3581-5. PubMed ID: 11325823
[TBL] [Abstract][Full Text] [Related]
28. Promoter methylation-mediated silencing of β-catenin enhances invasiveness of non-small cell lung cancer and predicts adverse prognosis.
Miao Y; Wang L; Zhang X; Xu X; Jiang G; Fan C; Liu Y; Lin X; Yu J; Zhang Y; Wang E
PLoS One; 2014; 9(11):e112258. PubMed ID: 25396757
[TBL] [Abstract][Full Text] [Related]
29. Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival.
Brabender J; Usadel H; Danenberg KD; Metzger R; Schneider PM; Lord RV; Wickramasinghe K; Lum CE; Park J; Salonga D; Singer J; Sidransky D; Hölscher AH; Meltzer SJ; Danenberg PV
Oncogene; 2001 Jun; 20(27):3528-32. PubMed ID: 11429699
[TBL] [Abstract][Full Text] [Related]
30. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation.
Soria JC; Lee HY; Lee JI; Wang L; Issa JP; Kemp BL; Liu DD; Kurie JM; Mao L; Khuri FR
Clin Cancer Res; 2002 May; 8(5):1178-84. PubMed ID: 12006535
[TBL] [Abstract][Full Text] [Related]
31. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K
Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757
[TBL] [Abstract][Full Text] [Related]
32. Epigenetic inactivation of checkpoint kinase 2 gene in non-small cell lung cancer and its relationship with clinicopathological features.
Kim DS; Kim MJ; Lee JY; Lee SM; Choi JE; Lee SY; Park JY
Lung Cancer; 2009 Aug; 65(2):247-50. PubMed ID: 19362748
[TBL] [Abstract][Full Text] [Related]
33. [Effects of 5-Aza-2-deoxycytidine on DNA methylation of anti-oncogenes in non-small cell lung cancer cells].
Fang HL; Yu ZC; Zhu HB; Jin YT
Zhonghua Zhong Liu Za Zhi; 2012 Sep; 34(9):658-63. PubMed ID: 23159077
[TBL] [Abstract][Full Text] [Related]
34. Aberrant promoter methylation of multiple genes in non-small cell lung cancers.
Zöchbauer-Müller S; Fong KM; Virmani AK; Geradts J; Gazdar AF; Minna JD
Cancer Res; 2001 Jan; 61(1):249-55. PubMed ID: 11196170
[TBL] [Abstract][Full Text] [Related]
35. Deregulated expression of c-mos in non-small cell lung carcinomas: relationship with p53 status, genomic instability, and tumor kinetics.
Gorgoulis VG; Zacharatos P; Mariatos G; Liloglou T; Kokotas S; Kastrinakis N; Kotsinas A; Athanasiou A; Foukas P; Zoumpourlis V; Kletsas D; Ikonomopoulos J; Asimacopoulos PJ; Kittas C; Field JK
Cancer Res; 2001 Jan; 61(2):538-49. PubMed ID: 11212247
[TBL] [Abstract][Full Text] [Related]
36. FHIT promoter methylation status, low protein and high mRNA levels in patients with non-small cell lung cancer.
Czarnecka KH; Migdalska-Sęk M; Domańska D; Pastuszak-Lewandoska D; Dutkowska A; Kordiak J; Nawrot E; Kiszałkiewicz J; Antczak A; Brzeziańska-Lasota E
Int J Oncol; 2016 Sep; 49(3):1175-84. PubMed ID: 27572663
[TBL] [Abstract][Full Text] [Related]
37. Promoter methylation of APC and RAR-β genes as prognostic markers in non-small cell lung cancer (NSCLC).
Feng H; Zhang Z; Qing X; Wang X; Liang C; Liu D
Exp Mol Pathol; 2016 Feb; 100(1):109-13. PubMed ID: 26681652
[TBL] [Abstract][Full Text] [Related]
38. Promoter methylation of RASSF1A and DAPK and mutations of K-ras, p53, and EGFR in lung tumors from smokers and never-smokers.
Liu Y; Gao W; Siegfried JM; Weissfeld JL; Luketich JD; Keohavong P
BMC Cancer; 2007 May; 7():74. PubMed ID: 17477876
[TBL] [Abstract][Full Text] [Related]
39. Aberrant Hypermethylation at Sites -86 to 226 of DAB2 Gene in Non-Small Cell Lung Cancer.
Li C; Chen J; Chen T; Xu Z; Xu C; Ding C; Wang Y; Lei Z; Zhang HT; Zhao J
Am J Med Sci; 2015 May; 349(5):425-31. PubMed ID: 25719979
[TBL] [Abstract][Full Text] [Related]
40. Aberrant methylation of TMS1 in small cell, non small cell lung cancer and breast cancer.
Virmani A; Rathi A; Sugio K; Sathyanarayana UG; Toyooka S; Kischel FC; Tonk V; Padar A; Takahashi T; Roth JA; Euhus DM; Minna JD; Gazdar AF
Int J Cancer; 2003 Aug; 106(2):198-204. PubMed ID: 12800194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
